New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow ...

Mario Germano Giuliani and Lisa Giuliani have made an extraordinary gift of $27.8 million to support research in multiple myeloma, Dana-Farber Cancer Institute announced today. It is one of the ...

If you are a journalist and have a question about this story, please call 617-632-4090 and ask to speak to a member of the media team, or email media@dfci.harvard.edu.

Daraxonrasib is the first approved RAS-targeted therapy in pancreatic cancer Approval based primarily on Dana-Farber-led RASolute 302 trial showing daraxonrasib nearly doubled med ...

The U.S. Food and Drug Administration has approved iberdomide in combination with daratumumab and dexamethasone for patients with relapsed or refractory multiple myeloma, making it the first approved ...

Dana-Farber Brigham Cancer Center has been recognized as the Best Hospital for Cancer in Massachusetts and ranked #3 in the nation by U.S. News & World Report. This is the 26th consecutive year ...

The National Cancer Institute (NCI) Office of Grants Administration (OGA) manages over $3 billion in awards annually to fund cancer research. They direct the negotiation and administration of grants ...

Small clinical trial led by Dana-Farber Cancer Institute builds on Salk Institute’s foundational research on vitamin D receptor and tumor microenvironment A small clinical trial led by Dana-Farber ...

Dana-Farber Cancer Institute and Mayor Michelle Wu today announced new funding to help preserve access to comprehensive early cancer detection services for Boston firefighters. Through a $150,000 ...

Dana-Farber Cancer Institute announced that Larry and Susan Marx have made a $5 million gift to support cancer prevention and early detection. This commitment will establish the Larry and Susan Marx ...